Loading
KSQ-004EX is an experimental engineered immune-cell therapy from KSQ Therapeutics, in phase 1 trials for selected advanced solid tumours.
KSQ-004EX is an autologous CRISPR/Cas9-engineered tumour-infiltrating lymphocyte (eTIL) therapy from KSQ Therapeutics. Tumour-infiltrating lymphocytes with both the Regnase-1 and SOCS1 genes switched off by CRISPR/Cas9. Its phase 1/2 study (NCT06598371) is recruiting; the company's pipeline lists melanoma, lung, head and neck, colorectal, pancreatic and cervical cancers. OnCo has no Regnase-1 target record. Whether it works in people has not been established.
Tumour-infiltrating lymphocytes with both the Regnase-1 and SOCS1 genes switched off by CRISPR/Cas9. Connects to SOCS1.
1.KSQ-004EX slips into a pocket on SOCS1.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"KSQ-004EX" OR ABSTRACT:"KSQ-004EX") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about KSQ-004EX, not a curated reading list.
Shares SOCS1, KSQ Therapeutics and the tag pipeline.
Shares KSQ Therapeutics and the tag pipeline.
Shares KSQ Therapeutics and the tag pipeline.
Shares KSQ Therapeutics and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/